Myeloma

Dr. Neparidze obtained her medical degree from Aieti Medical School in Tbilisi, Georgia in 2000. She subsequently completed Postdoctoral Research Fellowships at Emory, Northwestern and Yale Universities, followed by Internal Medicine Residency and Hematology/Medical Oncology Fellowship at Yale University. She has served as an assistant professor at Yale University School of Medicine, Medical Oncology/Hematology since 2012.  She specializes in multiple myeloma, monoclonal gammopathies, AL amyloidosis, Waldenstrom's macroglobulinemia.  Dr. Neparidze has developed multiple research projects in myeloma, including a number of investigator-initiated therapeutic clinical trials. She collaborates with other researchers nationally and internationally, serve as a PI and co-PI on multiple therapeutic clinical trials and leads several clinical outcomes studies in patients with myeloma. She serves as the leader of the Yale Myeloma Research team.  Her ongoing research directions include use of advanced imaging and evaluating tumor heterogeneity to enhance precision medicine approaches for myeloma, novel combination immunotherapy strategies and MRD-driven therapies in myeloma, as well as studying biology and clinical outcomes of monoclonal gammopathies in association with metabolic, viral and other co-morbidities, investigating mechanisms of tumor progression and resistance in myeloma. Dr. Neparidze is actively involved in educational process, teaching Hematology/Oncology fellows, medical students, residents and colleagues at Yale and in community. Learn more about Dr. Neparidze>>

Noffar Bar, MD, is an Assistant Professor of Medicine (Hematology) at Yale School of Medicine and completed her internship and residency at the Mount Sinai Hospital and her fellowship at Yale. She received her medical degree from the American Medical Program at Tel Aviv University in New York. Dr. Bar is a member of the American Society of Clinical Oncology, the American Society of Hematology, and the International Myeloma Society. Dr. Bar’s research is focused on multiple myeloma and other plasma cell disorders. She specializes in all treatment modalities for myeloma including CAR T-cell therapy and stem cell transplant. She received grant support through the Conquer Cancer Foundation’s Young Investigator Award for her work looking at the prevention of multiple myeloma. Dr. Bar is dedicated to improving treatments for myeloma patients through innovative clinical trials. Additionally, Dr. Bar is a medical educator and a member of the Classical Hematology Disease team at Yale. She is interested in promoting high value care for hematology patients.

Dr. Sabrina Browning received her medical degree from the University of Connecticut School of Medicine where she first confirmed her passion for caring for individuals with hematologic diseases. Her internship and residency were completed at Yale New Haven Hospital. After residency, Dr. Browning served as Amyloid Fellow at the internationally recognized Amyloidosis Center at Boston University School of Medicine and Boston Medical Center. In this position, she played a key role in the multidisciplinary care of and coordination for patients with immunoglobulin light chain (AL) amyloidosis and related diseases. She returned to Yale New Haven Hospital to complete her fellowship in Medical Oncology and Hematology. Upon joining as faculty in the Hematology section at Yale School of Medicine, Dr. Browning was the sole awardee of the Bernard Forget Scholarship for 2020-2021, which supports deserving individuals who are transitioning into an academic career in Hematology. Dr. Browning is a physician in the Smilow Multiple Myeloma and Gammopathies Programs and also sees patients in the Classical Hematology Clinic and she is incredibly passionate about the comprehensive management of patients with rare hematologic disorders including AL amyloidosis and hereditary hemorrhagic telangiectasia or HHT. Dr. Browning’s clinical and research interests include evaluating new treatments for multiple myeloma, AL amyloidosis, and other hematologic diseases and their impact on outcomes and quality of life for patients. With the support of the Frederick DeLuca Foundation and the DeLuca Center for Innovation in Hematology Research, she is also studying the association between metabolic syndrome, which can include obesity, high blood pressure, high cholesterol, and diabetes, and the development of monoclonal gammopathy and multiple myeloma with the aim to learn more about potential preventative strategies. Dr. Browning has a clinical and research interest in the management of issues such as bleeding and clotting in individuals with multiple myeloma and AL amyloidosis. Dr. Browning serves as the Principal Investigator on several clinical trials here at Yale for patients with multiple myeloma and AL amyloidosis and is interested in design of new clinical trials to further help her patients and others living with these diseases. Dr. Browning serves as the representative for the Yale Cancer Center on the Faculty Advisory Council for Yale School of Medicine. She is a member of the American Society of Hematology (ASH), the International Myeloma Society (IMS), and the International Society of Amyloidosis (ISA). As a member of the HHT center here at Yale she is also a registered physician with CureHHT. Dr. Browning is dedicated to providing patient-centered and compassionate care to individuals and their families through a team-based approach. She is also committed to teaching trainees at various levels of medical training.

Dr. Neparidze obtained her medical degree from Aieti Medical School in Tbilisi, Georgia in 2000. She subsequently completed Postdoctoral Research Fellowships at Emory, Northwestern and Yale Universities, followed by Internal Medicine Residency and Hematology/Medical Oncology Fellowship at Yale University. She has served as an assistant professor at Yale University School of Medicine, Medical Oncology/Hematology since 2012.  She specializes in multiple myeloma, monoclonal gammopathies, AL amyloidosis, Waldenstrom's macroglobulinemia.  Dr. Neparidze has developed multiple research projects in myeloma, including a number of investigator-initiated therapeutic clinical trials. She collaborates with other researchers nationally and internationally, serve as a PI and co-PI on multiple therapeutic clinical trials and leads several clinical outcomes studies in patients with myeloma. She serves as the leader of the Yale Myeloma Research team.  Her ongoing research directions include use of advanced imaging and evaluating tumor heterogeneity to enhance precision medicine approaches for myeloma, novel combination immunotherapy strategies and MRD-driven therapies in myeloma, as well as studying biology and clinical outcomes of monoclonal gammopathies in association with metabolic, viral and other co-morbidities, investigating mechanisms of tumor progression and resistance in myeloma. Dr. Neparidze is actively involved in educational process, teaching Hematology/Oncology fellows, medical students, residents and colleagues at Yale and in community. Learn more about Dr. Neparidze>>

Dr. Seropian is a Professor of Medicine in the department of Internal Medicine, Section of Hematology, Yale University School of Medicine. He received his medical degree from George Washington University School of Medicine and completed residency and fellowship training at Yale-New Haven Hospital/Yale University School of Medicine in 1996.  Dr. Seropian serves as Interim Director of the Stem Cell Transplant Program, Co-Director, Immune Effector Cell Therapy, and Chairman, Car-T Cell Joint Steering Committee, Yale-New Haven Hospital. Dr. Seropian’s research interests include methods to improve the outcomes of transplantation through use of novel anti-cancer agents and new methods of treating graft versus host disease